glp-1 va coverage MCT2D Designing fiscally viable coverage of

A Pipeline Teeming with Innovation Beyond todays leading therapies like Mounjaro, Zepbound, Ozempic, and Wegovy, a robust pipeline of next-generation obesity drugs is advancing through clinical development, with several candidates already filed for regulatory approval

In clinical trial data, nausea, diarrhoea, constipation and vomiting are consistently among the most common side effects

Shen, C

Two numbers describe every needle: the gauge (how thick it is, where a higher number means a thinner needle) and the length (how deep it can reach)

& Lee, S.-H

Blue Cross Blue Shield and other major insurers frequently require prior authorization before covering tirzepatide, a GLP-1 receptor agonist shown in clinical trials to reduce body weight by 20% or more